Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 17/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25586414 | 0.84 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL25878873 | 0.82 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL25584880 | 0.80 | TDP1 (0.47) | TDP1PSMD14RXFP1RIPK1GPR84 | |
| SCHEMBL22968458 | 0.78 | RIPK1 (0.50) | RIPK1 | |
| SCHEMBL24076700 | 0.78 | RIPK1 (0.41) | RIPK1 | |
| SCHEMBL24076721 | 0.77 | RIPK1 (0.56) | RXFP1RIPK1 | |
| SCHEMBL22968464 | 0.77 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL21531314 | 0.76 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL21531311 | 0.76 | RIPK1 (0.55) | RIPK1 | |
| SCHEMBL22968453 | 0.74 | RIPK1 (0.53) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371430-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371430-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | TDP1 1005/4885PSMD14 1598/4885RXFP1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.